4.5 Article

Limited durability of viral control following treated acute HIV infection

Journal

PLOS MEDICINE
Volume 1, Issue 2, Pages 137-148

Publisher

PUBLIC LIBRARY SCIENCE
DOI: 10.1371/journal.pmed.0010036

Keywords

-

Funding

  1. NCRR NIH HHS [M01 RR000052, 5-M01-RR-00052] Funding Source: Medline
  2. NIAID NIH HHS [R01 AI044656, UO1-AI-35041, U01 AI035039, U01 AI035041, UO1-AI-35043, U01 AI037984, UO1-AI-37984, UO1-AI-37613, UO1-AI-35042, U01 AI035042, R01 AI050429, U01 AI035040, UO1-AI-35039, U01 AI035043, UO1-AI-35040, U01 AI037613, R01 AI 44656, R01 AI 29568] Funding Source: Medline

Ask authors/readers for more resources

Early treatment of acute HIV infection with highly active antiretroviral therapy, followed by supervised treatment interruption (STI), has been associated with at least transient control of viremia. However, the durability of such control remains unclear. Here we present longitudinal follow-up of a single-arm, open-label study assessing the impact of STI in the setting of acute HIV-1 infection. Methods and Findings Fourteen patients were treated during acute HIV-1 infection and subsequently subjected to an STI protocol that required retreatment if viral load exceeded 50,000 RNA copies/ml plasma or remained above 5,000 copies/ml for more than three consecutive weeks. Eleven of 14 (79%) patients were able to achieve viral loads of less than 5,000 RNA copies/ml for at least 90 d following one, two, or three interruptions of treatment. However, a gradual increase in viremia and decline in CD4+ T cell counts was observed in most individuals. By an intention-to-treat analysis, eight (57%), six (43%), and three (21%) of 14 patients achieved a maximal period of control of 180, 360, and 720 d, respectively, despite augmentation of HIV-specific CD4+ and CD8+ T cell responses. The magnitude of HIV-1-specific cellular immune responses before treatment interruption did not predict duration of viremia control. The small sample size and lack of concurrent untreated controls preclude assessment of possible clinical benefit despite failure to control viremia by study criteria. Conclusions These data indicate that despite initial control of viremia, durable viral control to less than 5,000 RNA copies/ml plasma in patients following treated acute HIV-1 infection occurs infrequently. Determination of whether early treatment leads to overall clinical benefit will require a larger and randomized clinical trial. These data may be relevant to current efforts to develop an HIV-1 vaccine designed to retard disease progression rather than prevent infection since they indicate that durable maintenance of low-level viremia may be difficult to achieve.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.5
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available